AU2014207707B2 - Treating pulmonary conditions - Google Patents

Treating pulmonary conditions Download PDF

Info

Publication number
AU2014207707B2
AU2014207707B2 AU2014207707A AU2014207707A AU2014207707B2 AU 2014207707 B2 AU2014207707 B2 AU 2014207707B2 AU 2014207707 A AU2014207707 A AU 2014207707A AU 2014207707 A AU2014207707 A AU 2014207707A AU 2014207707 B2 AU2014207707 B2 AU 2014207707B2
Authority
AU
Australia
Prior art keywords
composition
leucine
methylxanthine
resveratrol
theophylline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014207707A
Other languages
English (en)
Other versions
AU2014207707A1 (en
Inventor
Brooke BAGGETT
Antje BRUCKBAUER
Michael ZEMEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nusirt Sciences Inc
Original Assignee
Nusirt Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nusirt Sciences Inc filed Critical Nusirt Sciences Inc
Publication of AU2014207707A1 publication Critical patent/AU2014207707A1/en
Application granted granted Critical
Publication of AU2014207707B2 publication Critical patent/AU2014207707B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014207707A 2013-01-15 2014-01-14 Treating pulmonary conditions Ceased AU2014207707B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752909P 2013-01-15 2013-01-15
US61/752,909 2013-01-15
PCT/US2014/011531 WO2014113404A1 (en) 2013-01-15 2014-01-14 Treating pulmonary conditions

Publications (2)

Publication Number Publication Date
AU2014207707A1 AU2014207707A1 (en) 2015-08-13
AU2014207707B2 true AU2014207707B2 (en) 2018-11-01

Family

ID=51210014

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014207707A Ceased AU2014207707B2 (en) 2013-01-15 2014-01-14 Treating pulmonary conditions

Country Status (6)

Country Link
US (3) US20150359771A1 (enExample)
EP (1) EP2945616B1 (enExample)
JP (1) JP2016505023A (enExample)
CN (1) CN105101958B (enExample)
AU (1) AU2014207707B2 (enExample)
WO (1) WO2014113404A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3466418A1 (en) 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
CN108452311A (zh) 2012-11-13 2018-08-28 纽斯尔特科学公司 用于增强能量代谢的组合物和方法
WO2014113404A1 (en) 2013-01-15 2014-07-24 Nusirt Sciences, Inc. Treating pulmonary conditions
WO2014152016A1 (en) 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
AU2014238377A1 (en) * 2013-03-15 2015-09-10 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators
US20150013695A1 (en) * 2013-07-10 2015-01-15 Ahkeo Ventures LLC Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same
MX2016011063A (es) 2014-02-27 2016-11-30 Nusirt Sciences Inc Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica.
CN107998110A (zh) * 2018-01-11 2018-05-08 上海市普陀区中心医院 白藜芦醇用于制备治疗或缓解慢性气道炎症性疾病用药物的用途
US10830778B2 (en) * 2018-05-24 2020-11-10 C Technologies, Inc. Slope spectroscopy standards
US10568352B1 (en) 2018-10-25 2020-02-25 Wiser Concepts, LLC Nutritional compositions and methods of treatment therewith
US11437483B2 (en) 2020-03-05 2022-09-06 Intel Corporation Gate-all-around integrated circuit structures having dual nanoribbon channel structures

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060173079A1 (en) * 2003-01-10 2006-08-03 Universiteit Van Maastricht Compositions and methods for improving the condition of patients suffering from copd and other diseases
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
IE58246B1 (en) 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB8919131D0 (en) 1989-08-23 1989-10-04 Riker Laboratories Inc Inhaler
CA2066951A1 (en) * 1991-04-26 1992-10-27 Kou Moriyama Edible composition
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US20010051654A1 (en) * 1997-09-25 2001-12-13 Elliott Peter J. Treatment of inflammatory and autoimmune diseases
JP3611456B2 (ja) 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
AU765909C (en) 1998-12-17 2004-09-23 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
JP2005511210A (ja) * 2001-12-07 2005-04-28 グラクソ　グループ　リミテッド 計量バルブ及び医薬定量吸入器及びその方法
CA2483464C (en) 2002-05-17 2011-12-20 Duke University Method for treating obesity
CN100453130C (zh) 2002-06-26 2009-01-21 精达制药公司 用于渗透性药物传递系统的最低顺应性和高容积效率的活塞
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US20070141150A1 (en) * 2003-12-30 2007-06-21 Raghupathi Kandarapu Pharmaceutical composition
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
AU2005265031A1 (en) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
JPWO2006049286A1 (ja) * 2004-11-02 2008-05-29 味の素株式会社 アレルギー性疾患予防・治療剤
BRPI0606736A2 (pt) * 2005-02-11 2009-07-21 Argenta Discovery Ltd combinação de compostos e esteróides de metilxantina para tratar doenças respiratórias crÈnicas
EA013474B1 (ru) 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
KR20080108487A (ko) 2006-02-28 2008-12-15 트르스티스 오브 보스톤 유니버시티 대사 조절인자 및 그의 용도
DE102006016903A1 (de) 2006-04-11 2007-10-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalator
EP2381951B1 (en) * 2009-01-28 2015-12-23 Life Science Nutrition AS Compositions and methods of treating viral infections
US20110064720A1 (en) * 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
US8173181B2 (en) * 2009-11-09 2012-05-08 Bio-Engineered Supplements & Nutrition, Inc. Method and composition for improved anabolism
EP2571499A1 (en) * 2010-05-18 2013-03-27 Mahmut Bilgic Pharmaceutical composition comprising n- acetylcysteine and a xanthine
EP3466418A1 (en) * 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
WO2014113404A1 (en) 2013-01-15 2014-07-24 Nusirt Sciences, Inc. Treating pulmonary conditions
AU2014238377A1 (en) 2013-03-15 2015-09-10 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060173079A1 (en) * 2003-01-10 2006-08-03 Universiteit Van Maastricht Compositions and methods for improving the condition of patients suffering from copd and other diseases
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug

Also Published As

Publication number Publication date
EP2945616A1 (en) 2015-11-25
CN105101958B (zh) 2019-05-17
US20150359771A1 (en) 2015-12-17
HK1217169A1 (zh) 2016-12-30
JP2016505023A (ja) 2016-02-18
AU2014207707A1 (en) 2015-08-13
WO2014113404A1 (en) 2014-07-24
CN105101958A (zh) 2015-11-25
EP2945616B1 (en) 2018-11-28
US20170368012A1 (en) 2017-12-28
EP2945616A4 (en) 2016-06-22
US9737501B2 (en) 2017-08-22
US20150018375A1 (en) 2015-01-15
US10039733B2 (en) 2018-08-07

Similar Documents

Publication Publication Date Title
AU2014207707B2 (en) Treating pulmonary conditions
US9895357B2 (en) Compositions, methods and kits for reducing lipid levels
US10646489B2 (en) Compositions and methods for increasing energy metabolism
US20220409647A1 (en) Compositions, methods and kits for altering adipocytes
HK1217169B (en) Treating pulmonary conditions
HK1212594B (en) Pde5 inhibitors and leucine or a leucine metabolite for use in the treatment of diabetes

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired